IGM Biosciences, Inc. (IGMS)

NASDAQ: IGMS · IEX Real-Time Price · USD
19.25
+0.46 (2.45%)
Jun 24, 2022 4:00 PM EDT - Market closed
2.45%
Market Cap 714.96M
Revenue (ttm) n/a
Net Income (ttm) -185.41M
Shares Out 37.14M
EPS (ttm) -5.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 565,523
Open 19.11
Previous Close 18.79
Day's Range 18.50 - 19.71
52-Week Range 12.67 - 93.98
Beta -0.14
Analysts Buy
Price Target 50.55 (+162.6%)
Earnings Date Aug 8, 2022

About IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody ... [Read more...]

Industry Biotechnology
IPO Date Sep 18, 2019
Employees 216
Stock Exchange NASDAQ
Ticker Symbol IGMS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is 50.55, which is an increase of 162.60% from the latest price.

Price Target
$50.55
(162.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference

MOUNTAIN VIEW, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced t...

Medivir to present at the ABGSC Life Science Summit

HUDDINGE, Sweden , May 17, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ABGSC Life Science Summit on May 18, 2022. The company will be re...

IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference

MOUNTAIN VIEW, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced th...

IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update

–   Closing of Global Collaboration Agreement with Sanofi; $150 Million Upfront Payment to IGM –

IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi

$150 Million Payment to IGM from Sanofi $150 Million Payment to IGM from Sanofi

Resolutions at the Annual General Meeting in Medivir on 5 May 2022

HUDDINGE, Sweden, May 5, 2022 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual shareholders' meeting today on 5 May 2022. The annual general meeting was held by physical presence of shareholder...

Medivir to present at the Redeye Orphan Drugs Conference

STOCKHOLM , April 25, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Redeye Orphan Drugs Conference on April 27, 2022. CEO Jens Lindberg wi...

IGM Announces Closing of $230.0 Million Public Offering

MOUNTAIN VIEW, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,...

Regeneron, IGM Biosciences Shares Up Big on Sanofi Deals

A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.

Other symbols: REGNSNY

Why Did Truist Lower IGM Biosciences' Price Target?

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ: IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal finan...

IGM Announces Pricing of $200.0 Million Public Offering

MOUNTAIN VIEW, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting commo...

8 Stocks Halted In Tuesday's Session

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and brin...

Other symbols: ALLGAMCFATGMEPCTVLNS

Why Is IGM Biosciences (IGMS) Stock Up Today?

Here are the various catalysts investors in IGM Biosciences and IGMS stock are watching today as shares more than double. The post Why Is IGM Biosciences (IGMS) Stock Up Today?

Why IGM Biosciences Stock Rocketed Higher Today

In addition to reporting its fourth-quarter results, the clinical-stage biotech announced a lucrative new collaboration deal with Sanofi.

These 2 Stocks Are Up 20%-Plus in Tuesday's Premarket

Upward momentum on Wall Street continued.

Other symbols: NLSN

IGM Announces Proposed Public Offering

MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu...

IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate De...

IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi

MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...

Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation ...

Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets

Other symbols: SNY

Why Did IGM Biosciences Shares Advance Today?

IGM Biosciences Inc IGMS has progressed two Phase 1 trials evaluating IGM-6268, an anti-SARS-CoV-2 IgM monoclonal antibody, to treat and prevent infection COVID-19.  Get the Inside Access Traders Are Us...

IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19

– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested –

IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference

MOUNTAIN VIEW, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

Here's Why IGM Biosciences, Inc. (IGMS) is Poised for a Turnaround After Losing 50.6% in 4 Weeks

IGM Biosciences, Inc. (IGMS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...

IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American S...

- Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile -